Moderna, Inc. $MRNA Shares Acquired by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 16.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,917 shares of the company’s stock after purchasing an additional 3,126 shares during the period. Maryland State Retirement & Pension System’s holdings in Moderna were worth $4,221,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Advisor Resource Council acquired a new stake in shares of Moderna in the third quarter valued at approximately $283,000. Ritholtz Wealth Management boosted its stake in Moderna by 162.7% during the third quarter. Ritholtz Wealth Management now owns 9,001 shares of the company’s stock worth $1,733,000 after buying an additional 5,575 shares during the last quarter. Joel Isaacson & Co. LLC acquired a new position in Moderna during the third quarter worth $240,000. Jacobi Capital Management LLC acquired a new position in Moderna during the third quarter worth $75,000. Finally, First Command Advisory Services Inc. acquired a new position in Moderna during the third quarter worth $164,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MRNA. The Goldman Sachs Group upped their target price on Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a report on Monday, November 9th. Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. Loop Capital set a $135.00 price target on shares of Moderna in a research report on Wednesday, August 19th. William Blair cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Finally, TD Cowen reissued a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Moderna has an average rating of “Hold” and an average price target of $113.75.

Read Our Latest Research Report on MRNA

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the transaction, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company’s stock.

Top Moderna Stories

These are some of the MRNA stories that stood out recently:

  • Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
  • Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
  • Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Moderna Price Performance

Shares of NASDAQ MRNA opened at $223.37 on Monday. The company has a 50 day simple moving average of $201.67 and a 200-day simple moving average of $96.41. The company has a market capitalization of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. During the same quarter in the previous year, the company earned ($0.51) EPS. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. On average, equities research analysts predict that Moderna, Inc. will post -5.14 earnings per share for the current year.

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.